Neurocrine’s schizophrenia drug meets main goal in mid-stage study

Aug 28 (Reuters) – Neurocrine Biosciences (NBIX.O) said on Wednesday its experimental drug to treat adults with schizophrenia met the main goal in a mid-stage study.
 
A 20 milligram dose of the drug candidate, NBI-1117568, helped significantly reduce severity of symptoms compared to placebo in adult patients with the mental health condition, the company said.
 
The drug was generally safe and well tolerated at all doses tested in the study, Neurocrine said, adding that it plans to begin late-stage trials early next year.
 
/by
You might also like
brainXenon’s add-on epilepsy treatment shows promising Phase IIb efficacy, safety
PfizerPfizer starts late-stage trial of mRNA-based flu vaccine
GSK logoWith positive combo meningococcal vaccine data, GSK eyes US approval
handFoghorn abandons uveal melanoma program after subpar Phase I results
RocheRoche plots neuro comeback with promising mid-stage Alzheimer’s data
AlnyamFirst pill for dengue shows promise in human challenge trial
Brain scanPTC’s vatiquinone fails second trial in as many months
AlnyamAlnylam aces Phase III cardio trial, eyes label expansion for RNAi therapy